☆ 4.2 Editorial Material

Nivolumab plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastroesophageal junction cancer-regional differences in efficacy

ANNALS OF PALLIATIVE MEDICINE (2022)

Get Full Text
Add to Collection

Journal

ANNALS OF PALLIATIVE MEDICINE
Volume -, Issue -, Pages -

Publisher

AME PUBLISHING COMPANY
DOI: 10.21037/apm-22-851

Keywords

-

Categories

Health Care Sciences & Services

Funding

  1. Eli Lilly
  2. Merck
  3. Bristol Meyers Squibb
  4. Oncolys Biopharma

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.